Stockysis — AI-Powered Stock News & Sentiment Analysis

Stifel Maintains Buy on OptimizeRx, Lowers Price Target to $17

Benzinga Newsdesk www.benzinga.com Negative 70.1%

Neg 70.1% Neu 0% Pos 0%

Stifel analyst David Grossman maintains OptimizeRx (NASDAQ:OPRX) with a Buy and lowers the price target from $21 to $17.

Comments

No comments yet. Be the first!